Truist Raises CG Oncology Target to $100
The target increase and implied upside are bullish, but remain an analyst forecast rather than a guaranteed outcome.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The target increase and implied upside are bullish, but remain an analyst forecast rather than a guaranteed outcome.
What happened, with direct paths to the underlying reporting
Truist raised its target to $100 versus a posted price of $76.82, implying about 30% upside to the new target.
Target: $100
Posted price: $76.82
Analyst firm: Truist Financial
Analyst: Greg Renza
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.